PMID- 10629414
OWN - NLM
STAT- MEDLINE
DCOM- 20000225
LR  - 20171101
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 29 Suppl S1
DP  - 1999 Dec
TI  - Should patients with venous thromboembolism and cancer be treated differently?
PG  - 91-7
AB  - Patients with malignant disease constitute a significant subgroup among patients 
      with venous thromboembolism. Current results suggest that cancer patients are not 
      only at an increased risk for thromboembolic events, particularly during 
      chemotherapy treatment or after surgery, they also have an increased risk for 
      bleeding complications while receiving oral anticoagulant treatment. The exact 
      incidences of venous thromboembolic complications for the various types of 
      cancer, however, are not well determined. Recent studies have indicated that 
      subcutaneous low-molecular-weight heparin (LMWH) is as safe and effective as 
      intravenous unfractionated heparin (UFH) in the initial treatment of venous 
      thromboembolism. Moreover, a meta-analysis has provided preliminary evidence 
      that, compared with UFH, LMWH treatment may prolong survival in cancer patients. 
      Initiation of LMWH treatment in these patients is, therefore, recommended. 
      Prospective randomized clinical trials to assess the optimum dose and duration of 
      therapy are called for.
CI  - Copyright 1999 S. Karger AG, Basel
FAU - Smorenburg, S M
AU  - Smorenburg SM
AD  - Department of Vascular Medicine and Cell Biology and Histology, Academic Medical 
      Centre, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Hutten, B A
AU  - Hutten BA
FAU - Prins, M H
AU  - Prins MH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Neoplasms/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Venous Thrombosis/*drug therapy
RF  - 38
EDAT- 2000/01/12 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/01/12 09:00
PHST- 2000/01/12 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/01/12 09:00 [entrez]
AID - 54122 [pii]
AID - 10.1159/000054122 [doi]
PST - ppublish
SO  - Haemostasis. 1999 Dec;29 Suppl S1:91-7. doi: 10.1159/000054122.